Capecitabine reverses tumor escape from anti-VEGF through the eliminating CD11bhigh/Gr1high myeloid cells

Pharmacology, Toxicology and Pharmaceutical Science

• Antiangiogenic Therapy 12%
• Antibody 12%
• Anticarcinogen 12%
• Bevacizumab 12%
• Capecitabine 50%
• Drug Resistance 12%
• Fluorouracil 25%
• Granulocyte Colony Stimulating Factor 25%
• Interleukin 17 12%
• Lewis Carcinoma 12%
• Mouse 12%
• Neoplasm 87%
• Preclinical Study 12%
• Prodrug 12%
• Tumor Growth 12%
• Tumor Resistance 12%
• Vasculotropin 100%
• Vasculotropin Antibody 12%

Immunology and Microbiology

• Angiogenesis 12%
• Bevacizumab 12%
• Cells 12%
• Drug Resistance 12%
• Granulocyte Colony-Stimulating Factor 25%
• Growth 12%
• Humanized Antibody 12%
• Interleukin 17 12%
• Lung 12%
• Mouse 12%
• Myeloid 12%
• Myeloid-Derived Suppressor Cell 50%
• Preclinical Study 12%
• Tumor Escape 25%
• Vasculotropin 100%
• Vasculotropin Antibody 12%

Biochemistry, Genetics and Molecular Biology

• Angiogenesis 12%
• Bevacizumab 12%
• Capecitabine 50%
• Drug Resistance 12%
• Fluorouracil 25%
• Granulocyte Colony-Stimulating Factor 25%
• Growth 12%
• Humanized Antibody 12%
• Interleukin 17 12%
• Mouse 12%
• Myeloid 12%
• Preclinical Study 12%
• Tumor Escape 25%